Joel Guigay

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint Advances in nasopharyngeal carcinoma
    Joel Guigay
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Curr Opin Oncol 20:264-9. 2008
  2. ncbi request reprint Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Fritz Line Velayoudom-Cephise
    Department of Nuclear Medicine and Endocrine Oncology, Villejuif, France
    Endocr Relat Cancer 20:649-57. 2013
  3. ncbi request reprint Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas
    Antonin Levy
    Department of Radiation Oncology, Gustave Roussy, 114 rue Edouard Vaillant, 94850, Villejuif, France
    Strahlenther Onkol 190:823-31. 2014
  4. ncbi request reprint Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging
    Ronan Abgral
    Department of Nuclear Medicine, University Hospital of Brest, 29200 Brest, France
    J Clin Endocrinol Metab 96:665-71. 2011
  5. ncbi request reprint Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes
    Frederic Peyrade
    Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
    Oral Oncol 49:482-91. 2013
  6. ncbi request reprint Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome
    Gabriel G Malouf
    Department of Radiotherapy, Institut de Cancerologie Gustave Roussy, Villejuif, France
    Eur J Cancer 49:1324-34. 2013
  7. ncbi request reprint Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma
    Nader Abedallaa
    Departments of Medicine and Biostatistics, Institut Gustave Roussy, Villejuif, France
    J Thorac Oncol 7:1179-83. 2012
  8. ncbi request reprint Intervention in gastro-enteropancreatic neuroendocrine tumours
    Eric Baudin
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Best Pract Res Clin Gastroenterol 26:855-65. 2012
  9. ncbi request reprint Targeted therapy-induced radiation recall
    Antonin Levy
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 49:1662-8. 2013
  10. pmc Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells
    Claire Gourzones
    Univ Paris Sud 11, CNRS UMR 8126 and Institut de Cancérologie Gustave Roussy, 39 rue Camille Desmoulins, Villejuif, France
    Virol J 7:271. 2010

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Advances in nasopharyngeal carcinoma
    Joel Guigay
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Curr Opin Oncol 20:264-9. 2008
    ..This review updates these recent advances in diagnosis and treatment of nasopharyngeal carcinoma...
  2. ncbi request reprint Are G3 ENETS neuroendocrine neoplasms heterogeneous?
    Fritz Line Velayoudom-Cephise
    Department of Nuclear Medicine and Endocrine Oncology, Villejuif, France
    Endocr Relat Cancer 20:649-57. 2013
    ..If confirmed, future classifications may consider splitting them into two groups according to their morphological differentiation...
  3. ncbi request reprint Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas
    Antonin Levy
    Department of Radiation Oncology, Gustave Roussy, 114 rue Edouard Vaillant, 94850, Villejuif, France
    Strahlenther Onkol 190:823-31. 2014
    ..The goal of the present work was to compare outcomes of definitive concurrent cisplatin-based chemoradiotherapy (CRT) with cetuximab-based bioradiotherapy (BRT) in locally advanced head-and-neck squamous cell carcinoma (HNSCC)...
  4. ncbi request reprint Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging
    Ronan Abgral
    Department of Nuclear Medicine, University Hospital of Brest, 29200 Brest, France
    J Clin Endocrinol Metab 96:665-71. 2011
    ....
  5. ncbi request reprint Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes
    Frederic Peyrade
    Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
    Oral Oncol 49:482-91. 2013
    ..Recently, new drugs have been incorporated in patient management, thus enabling an increase in OS. This review aims to define the comprehensive medical management of patients with relapsing head and neck carcinoma...
  6. ncbi request reprint Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome
    Gabriel G Malouf
    Department of Radiotherapy, Institut de Cancerologie Gustave Roussy, Villejuif, France
    Eur J Cancer 49:1324-34. 2013
    ..Esthesioneuroblastomas, also called olfactory neuroblastomas (ENB) represent a rare sinonasal neurectodermal tumour which prognostic factors are unsteadily described...
  7. ncbi request reprint Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma
    Nader Abedallaa
    Departments of Medicine and Biostatistics, Institut Gustave Roussy, Villejuif, France
    J Thorac Oncol 7:1179-83. 2012
    ..Surgical resection of an undiagnosed lung lesion may lead to unintentional removal of small-cell lung cancer (SCLC). The benefit of perioperative chemotherapy in resected SCLC or large-cell neuroendocrine carcinomas (LCNEC) is not clear...
  8. ncbi request reprint Intervention in gastro-enteropancreatic neuroendocrine tumours
    Eric Baudin
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Best Pract Res Clin Gastroenterol 26:855-65. 2012
    ..In the absence of cure at the metastatic stage, progresses are expected in the recognition of well differentiated NET subgroups that display either excellent or poor prognosis...
  9. ncbi request reprint Targeted therapy-induced radiation recall
    Antonin Levy
    Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 49:1662-8. 2013
    ..A diverse range of chemotherapies has been associated with RR but no case series with targeted therapies (TT) has been reported...
  10. pmc Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells
    Claire Gourzones
    Univ Paris Sud 11, CNRS UMR 8126 and Institut de Cancérologie Gustave Roussy, 39 rue Camille Desmoulins, Villejuif, France
    Virol J 7:271. 2010
    ..To address this question, we investigated by quantitative RT-PCR the status of 5 microRNAs from the BART family in exosomes released by NPC cells in vitro as well as in plasma samples from NPC xenografted nude mice and NPC patients...
  11. ncbi request reprint Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma
    Cosimo Durante
    Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy, Universite Paris XI, 94805 Villejuif Cedex, France
    Endocr Relat Cancer 16:585-97. 2009
    ..This study enables the stratification of metastatic GEP WDEC patients into distinct risk groups. These risk categories can be used to tailor therapeutic approaches and also to design and interpret clinical trials...